Investor Presentaiton

Cash Flows- Consolidated (In NT$ million) FY 2017 (Unaudited) FY 2016 (Audited) From Operating Actavities 972 1,665 Profit before tax 475 811 Depreciation & Amortization 434 447 Net change in working capital 209 449 From Investing Actavities (437) (202) Capital expenditure (402) (447) From Financing Actavities (314) (138) Short-term loans (584) (720) Long-term loans 518 803 Cash dividends (228) (219) Net Change in Cash 204 1,371 Beginning Balance 3,707 2,336 Ending Balance 3,911 3,707 22 22 Free Cash Flow 570 1,218 ScinoPharm

View entire presentation